Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (currently amended): A compound of Formula I:



I I

or a pharmaceutically acceptable salt, a hydrate, a solvate or an isomer, in which:

X^1 and X^2 are independently selected from the group consisting of -N= and $-CR^4=$, wherein R^4 is hydrogen or C_{1-4}alkyl;

L is selected from the group consisting of a bond, -O- and $-NR^5-$, wherein R^5 is hydrogen or C_{1-4}alkyl;

R^1 is selected from the group consisting of $-X^3NR^6R^7$, $-X^3OR^7$ and $-X^3R^7$, wherein X^3 is a bond or C_{1-4}alkylene, R^6 is hydrogen or C_{1-4}alkyl and R^7 is selected from the group consisting of C_{6-10}aryl and C_{5-6}heteroaryl; wherein any aryl or heteroaryl is optionally substituted with 1 to 3 radicals independently selected from the group consisting of halo, amino, C_{1-4}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy and halo-substituted C_{1-4}alkoxy, with the proviso that halo or halo-substituted C_{1-4}alkyl on C_{6-10}aryl is not in the *meta* position with respect to the N or the O substituent, when X^3 is a bond; and is not in the *meta* position with respect to the CH_2 substituent, when X^3 is CH_2.

R^2 is selected from the group consisting of hydrogen, halo, amino, C_{1-4}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy and halo-substituted C_{1-4}alkoxy; and

R^3 is selected from the group consisting of C_{3-8}heterocycloalkyl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{6-10}aryl-C_{0-4}alkyl and $-X^3NR^8R^8$, with the proviso that C_{6-10}aryl-C_{0-4}alkyl is C_{6-10}aryl-C_{1-4}alkyl when X_1 is CR^4 and X_2 is N; wherein any alkyl group is optionally substituted with 1 to 3 radicals selected from the group consisting of hydroxy, halo and amino; and any aryl, heteroaryl or heterocycloalkyl is optionally substituted with 1 to 3 radicals independently selected from the group consisting of halo, nitro, C_{1-4}alkyl, halo-substituted C_{1-4}alkyl, hydroxy-C_{1-6}alkyl, C_{1-4}alkoxy, halo-substituted C_{1-4}alkoxy, phenyl, C_{3-8}heterocycloalkyl, $-X^3C(O)NR^8R^8$, $-X^3C(O)NR^8R^9$, $-X^3C(O)R^9$, $-X^3S(O)NR^8R^8$, $-X^3NR^8R^9$, $-X^3NR^8R^8$, $-X^3S(O)_2NR^8R^8$, $-X^3S(O)_2R^8$, $-X^3S(O)_2R^9$, $-X^3SNR^8R^8$, $-X^3ONR^8R^8$, $-X^3C(O)R^8$, $-X^3NR^8C(O)R^8$, $-X^3NR^8S(O)_2R^8$, $-X^3S(O)_2NR^8R^9$, $X^3NR^8S(O)_2R^9$, $-X^3NR^8C(O)R^9$, $-X^3NR^8C(O)NR^8R^9$, $-X^3NR^8C(O)NR^8R^8$, $-X^3C(O)OR^8$, $=NOR^8$, $-X^3NR^8OR^8$, $-X^3NR^8(CH_2)_{1-4}NR^8R^8$, $-X^3C(O)NR^8(CH_2)_{1-4}NR^8R^8$, $-X^3C(O)NR^8(CH_2)_{1-4}R^9$, $-X^3C(O)NR^8(CH_2)_{1-4}OR^9$, $-X^3O(CH_2)_{1-4}NR^8R^8$, $-X^3C(O)NR^8(CH_2)_{1-4}OR^8$and $X^3NR^8(CH_2)_{1-4}R^9$; wherein phenyl can be further substituted by a radical selected from $-NR^8R^8$ or $-C(O)NR^8R^8$; X^3 is as described above; R^8 is hydrogen, C_{1-6}alkyl, hydroxy-C_{1-6}alkyl or C_{2-6}alkenyl; and R^9 is hydroxy, C_{6-10}aryl-C_{0-4}alkyl, C_{6-10}aryl-C_{0-4}alkyloxy, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-8}heterocycloalkyl-C_{0-4}alkyl or C_{3-8}cycloalkyl; wherein said aryl, heteroaryl, cycloalkyl, heterocycloalkyl or alkyl of R^9 is further optionally substituted by up to 2 radicals selected from the group consisting of halo, hydroxy, cyano, amino, nitro, C_{1-4}alkyl, hydroxy-C_{1-6}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy, halo-substituted C_{1-4}alkoxy, halo-alkyl-substituted-phenyl, benzoxy, C_{5-9}heteroaryl, C_{3-8}heterocycloalkyl, $-C(O)NR^8R^8$, $-S(O)_2NR^8R^8$, $-NR^8R^8$, $-C(O)R^{10}$ and $-NR^{11}R^{11}$, wherein R^{10} is C_{5-6}heteroaryl and R^{11} is hydroxy-C_{1-4}alkyl.~~; and~~

~~the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.~~

2 (withdrawn): The compounds of claim 1 of Formula Ia:



(Ia)

in which

L is a bond;

R^1 is selected from the group consisting of $-NHR^7$, $-OR^7$ and $-R^7$, wherein R^7 is phenyl or pyridinyl, optionally substituted with 1 to 3 radicals independently selected from the group consisting of halo, amino, C_{1-4}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy and halo-substituted C_{1-4}alkoxy;

R^2 is hydrogen or C_{1-4}alkyl; and

R^3 is C_{6-10}aryl-C_{0-4}alkyl, optionally substituted with 1 to 3 radicals independently selected from the group consisting of $-C(O)NR^8R^8$, $-C(O)NR^8R^9$, $-C(O)R^9$ and $-C(O)NR^8(CH_2)_2NR^8R^8$, wherein R^8 is hydrogen, C_{1-6}alkyl or hydroxy-C_{1-6}alkyl; and R^9 is C_{3-8}heterocycloalkyl-C_{0-4}alkyl, optionally substituted by $-C(O)NR^8R^8$.

3 (withdrawn): The compounds of claim 2 in which

R^1 is $-NHR^7$, wherein R^7 is phenyl substituted with halo-substituted C_{1-4}alkyl or halo-substituted C_{1-4}alkoxy;

R^2 is hydrogen; and

R^3 is phenyl substituted with $-C(O)NH(CH_2)_2OH$, $-C(O)NHR^9$, $-C(O)R^9$ or $-NH(CH_2)_2N(CH_3)_2$, wherein R^9 is morpholino-ethyl or piperidinyl, substituted with $-C(O)NH_2$.

4 (withdrawn): The compounds of claim 1 of Formula Ib:



(Ib)

in which

L is a bond;

R^1 is selected from the group consisting of $-NHR^7$, $-OR^7$ and $-R^7$, wherein R^7 is phenyl or pyridinyl optionally substituted with 1 to 3 radicals independently selected from the group consisting of halo, amino, C_{1-4}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy and halo-substituted C_{1-4}alkoxy;

R^2 is hydrogen or C_{1-4}alkyl; and

R^3 is selected from C_{5-6}heteroaryl-C_{0-4}alkyl or C_{6-10}aryl-C_{0-4}alkyl; wherein any aryl or heteroaryl is optionally substituted with 1 to 3 radicals selected from the group consisting of C_{3-8}heterocycloalkyl, $-C(O)NR^8R^8$, $-C(O)NR^8R^9$, $-C(O)R^9$, $-NR^8R^9$ and $-NR^8(CH_2)_2NR^8R^8$, wherein R^8 is hydrogen, C_{1-6}alkyl or hydroxy-C_{1-6}alkyl; and R^9 is C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-8}heterocycloalkyl-C_{0-4}alkyl or C_{3-8}cycloalkyl; wherein any aryl, heteroaryl, cycloalkyl, heterocycloalkyl or alkyl of R^9 is further optionally substituted by up to 2 radicals selected from the group consisting of hydroxy, C_{1-4}alkyl, hydroxy-C_{1-6}alkyl, C_{3-8}heterocycloalkyl, $-C(O)NR^8R^8$ and $-S(O)_2NR^8R^8$.

5 (withdrawn): The compounds of claim 4 in which

R^1 is $-NHR^7$, wherein R^7 is phenyl substituted with halo-substituted C_{1-4}alkyl or halo-substituted C_{1-4}alkoxy;

R^2 is hydrogen; and

R^3 is pyridinyl or phenyl, optionally substituted with 1 to 3 radicals selected from the group consisting of $-C(O)NH(CH_2)_2OH$, $-C(O)NHCH(C_3H_7)_2CH_2OH$, $-C(O)NH(CH_2)_2CH_3$, $-C(O)N(CH_3)_2$, $-C(O)NH(CH_2)_2N(CH_3)_2$, $-C(O)NHR^9$, $-C(O)N(C_2H_5)R^9$ and $-C(O)R^9$, wherein

R^9 is phenyl, phenethyl, pyridinyl, pyrrolidinyl, piperidinyl, morpholino or morpholino-ethyl; wherein any aryl, heteroaryl, heterocycloalkyl or alkyl of R^9 is further optionally substituted by up to 2 radicals selected from the group consisting of hydroxy, C_{1-4}alkyl, $-CH_2OH$, $-(CH_2)_2OH$, pyrrolidinyl, piperazinyl, $-C(O)NH_2$, $-C(O)N(C_2H_5)_2$ and $-S(O)_2NH_2$.

6 (currently amended): The compounds of claim 1 of Formula Ic:


(Ic)


(Ic)

in which

L is a bond, $-NH-$, $-N(C_2H_5)-$ or $-O-$;

R^1 is selected from the group consisting of $-NHR^7$, $-OR^7$ and $-R^7$, wherein R^7 is phenyl or pyridinyl, optionally substituted with 1 to 3 radicals independently selected from the group consisting of halo, amino, C_{1-4}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy and halo-substituted C_{1-4}alkoxy; and

R^2 is hydrogen or C_{1-4}alkyl.

7 (original): The compounds of claim 6 in which

L is a bond; and

R^3 is selected from the group consisting of C_{3-8}heterocycloalkyl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl and C_{6-10}aryl-C_{0-4}alkyl; wherein any aryl, heteroaryl or heterocycloalkyl is optionally substituted with 1 to 3 radicals independently selected from the group consisting of halo, nitro, C_{1-4}alkyl, hydroxy-C_{1-6}alkyl, C_{1-4}alkoxy, C_{3-8}heterocycloalkyl, $-X^3C(O)NR^8R^8$, $-X^3C(O)NR^8R^9$,$-X^3NR^8R^9$, $-X^3NR^8R^8$, $-X^3S(O)_2NR^8R^8$, $-X^3S(O)_2R^8$, $-X^3S(O)_2R^9$, $-X^3C(O)R^8$, $-X^3NR^8C(O)R^8$, $-X^3NR^8S(O)_2R^8$, $-X^3S(O)_2NR^8R^9$, $-X^3NR^8S(O)_2R^9$, $-X^3NR^8C(O)R^9$, $-X^3NR^8C(O)NR^8R^9$, $-X^3NR^8C(O)NR^8R^8$, $-X^3C(O)OR^8$, $=NOR^8$, $-X^3NR^8(CH_2)_{1-4}NR^8R^8$, $-X^3C(O)NR^8(CH_2)_{1-4}NR^8R^8$ and $-X^3O(CH_2)_{1-4}NR^8R^8$; R^8 is hydrogen, C_{1-6}alkyl or

hydroxy-C_{1-6}alkyl; R^9 is C_{6-10}aryl-C_{0-4}alkyl, C_{6-10}aryl-C_{0-4}alkyloxy, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-8}heterocycloalkyl-C_{0-4}alkyl or C_{3-8}cycloalkyl; wherein said aryl, heteroaryl, cycloalkyl, heterocycloalkyl or alkyl of R^9 is further optionally substituted by up to 2 radicals selected from the group consisting of halo, hydroxy, cyano, nitro, C_{1-4}alkyl, hydroxy-C_{1-6}alkyl, halo-substituted C_{1-4}alkyl, C_{1-4}alkoxy, halo-alkyl-substituted-phenyl, benzoxy, C_{5-9}heteroaryl, C_{3-8}heterocycloalkyl, $-C(O)NR^8R^8$, $-S(O)_2NR^8R^8$, $-NR^8R^8$ and $-C(O)R^{10}$, wherein R^{10} is C_{5-6}heteroaryl.

8 (original): The compounds of claim 7 in which R^3 is selected from the group consisting of morpholino, 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, 4-oxo-piperidin-1-yl, piperazinyl, pyrrolidinyl, pyridinyl, phenyl, naphthyl, thiophenyl, benzofuran-2-yl, benzo[1,3]dioxolyl, piperidinyl, pyrazinyl, pyrimidinyl, imidazolyl, pyrazolyl and 1*H*-benzoimidazolyl; wherein any aryl, heteroaryl or heterocycloalkyl is optionally substituted with 1 to 2 radicals independently selected from the group consisting of chloro, methyl, ethyl, hydroxymethyl, methoxy, -C(O)OH, -C(O)H, $-C(O)OCH_3$, $-C(O)N(C_2H_5)_2$, $-C(O)N(CH_3)_2$, $-C(O)NHCH_3$, $-S(O)_2NH_2$, $-S(O)_2CH_3$, chloro, $-NH_2$, $-C(O)CH_3$, $=NOCH_3$, $-NH(CH_2)_2N(CH_3)_2$, $-NH(CH_2)_3NH_2$, $-NH(CH_2)_2OH$, $-C(O)NH(CH_2)_2N(CH_3)_2$, $-NHR^9$, $-O(CH_2)_2N(CH_3)_2$, morpholino, piperazinyl, $-NHC(O)CH_3$, $-NHC(O)NHC_4H_9$, $-C(O)NHC_4H_9$, $-C(O)NHC_3H_7$, $-C(O)NHC_5H_{10}OH$, $-C(O)N(C_2H_4OH)_2$, $-C(O)NHC_2H_4OH$, $-C(O)NH(CH_2)_2OH$, $-NHC(O)R^9$, $-C(O)NHR^9$, $-NHC(O)NHR^9$, $-C(O)R^9$, $-NHS(O)_2C_4H_9$, $-NHS(O)_2CH_3$, $-NHS(O)_2R^9$, $-S(O)_2R^9$, $-S(O)_2NHR^9$, $-C(O)NH_2$ and $-C(O)NH(CH_2)_2N(CH_3)_2$; R^9 is phenethyl, 2-phenoxy-ethyl, 1H-imidazolyl-propyl, pyridinyl, pyridinyl-methyl, quinolinyl, morpholino, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydro-furan-2-ylmethyl, furan-2-ylmethyl, thiazol-2-ylmethyl, benzo[1,3]dioxol-5-ylmethyl, benzo[1,3]dioxol-5-yl, 3-(2-oxo-pyrrolidin-1-yl)-propyl, 3-imidazol-1-yl-propyl, 3H-pyrazol-3-yl, morpholino-ethyl, phenyl, thiophenyl-methyl, benzyl, cyclohexyl or furan-2-ylmethyl; wherein said aryl, heteroaryl, cycloalkyl, heterocycloalkyl or alkyl of R^9 is further optionally substituted by up to 2 radicals selected from hydroxy-methyl, hydroxy-ethyl, isobutyl, nitro, amino, hydroxyl, methoxy, trifluoromethoxy, cyano, isopropyl, methyl, ethyl,

chloro, fluoro, pyridinyl, morpholino, phenoxy, pyrrolidinyl, trifluoromethyl, trifluoromethyl-substituted-phenyl, $-N(CH_3)_2$, $-C(O)NH_2$, $-S(O)_2NH_2$, $-C(O)N(CH_3)_2$, cyano or $-C(O)R^{10}$; and R^{10} is furanyl.

9 (original): The compounds of claim 6 in which

L is -NH-, $-N(C_2H_5)-$ or -O-; and

R^3 is selected from the group consisting of C_{5-10}heteroaryl-C_{0-4}alkyl and C_{6-10}aryl-C_{0-4}alkyl; wherein any aryl or heteroaryl is optionally substituted with 1 to 3 radicals independently selected from the group consisting of C_{1-4}alkoxy, C_{3-8}heterocycloalkyl, $-X^3C(O)NR^8R^8$,$-X^3S(O)_2NR^8R^8$, $-X^3NR^8C(O)R^8$ and $-X^3NR^8C(O)NR^8R^9$; R^8 is hydrogen or C_{1-6}alkyl; and R^9 is C_{6-10}aryl-C_{0-4}alkyl optionally substituted by up to 2 halo-substituted C_{1-4}alkyl radicals.

10 (original): The compounds of claim 9 in which R^3 is selected from the group consisting of quinolinyl, pyridinyl and phenyl; wherein any aryl or heteroaryl is optionally substituted with 1 to 2 radicals independently selected from the group consisting of morpholino, methoxy, $-C(O)NH_2$, $-NHC(O)NHR^9$ and $-S(O)_2NH_2$; and R^9 is phenyl substituted by trifluoromethyl.

11 (original): A pharmaceutical composition for the treatment of tumors in warm-blooded animals, comprising an effective amount of a compound of claim 1.

12 (currently amended): A method of treating a subject ~~treatment of warm-blooded animals~~ suffering from leukemia ~~a tumoral disease~~, said method comprising administering to the subject ~~treating warm-blooded animals~~ in need of such treatment ~~with~~ an effective ~~tumor-inhibiting~~ amount of a compound of claim 1, wherein said compound of claim 1 inhibits Bcr-abl.

13 (cancelled)

14 (cancelled)

15 (original): A method of inhibiting Bcr-abl activity, the method comprising contacting Bcr-abl with a compound that binds to a myristoyl binding pocket of Bcr-abl.

16 (original): The method of claim 15, wherein the compound is a compound of claim 1.

17 (currently amended): A process for preparing a compound of claim 1, said process comprising:

(a) reacting a compound of Formula 2 with a compound of Formula 3, 4, 5 or 6 in the presence of a catalyst or a base:


(2)


(2)

$R^3-B(OH)_2$ (3) R^3-SnBu_3 (4) R^3-OH (5) R^3-NR^5H (6)

in which X^1, X^2, R^1, R^2, R^3 and R^5 are as defined for Formula I above with the proviso that R^2 is not halo, halo-substituted C_{1-4}alkyl or halo-substituted C_{1-4}alkoxy when said step (a) comprises reacting a compound of Formula 2 with a compound of Formula 3 or 4 and Q represents a fluoro, chloro, bromo or iodo; or

(b) optionally converting a compound of the invention into a pharmaceutically acceptable salt;

(c) optionally converting a salt form of a compound of the invention to a non-salt form;

(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;

(e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form; and

(f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers.

~~(g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and~~

~~(h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.~~

18. (new) A process for preparing a compound of claim 1, said process comprising:

(a) reacting a compound of Formula 2 with a compound of Formula 7:



(2) (7)

(b) optionally converting a compound of the invention into a pharmaceutically acceptable salt;

(c) optionally converting a salt form of a compound of the invention to a non-salt form;

(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;

(e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form; and

(f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers.

19 (new): The method of claim 12, wherein the leukemia is selected from chronic myeloid leukemia and acute lymphoblastic leukemia.